Amgen Says 24-Week Study Of Monthly Maritide In People With Type 2 Diabetes Showed Robust, Clinically Meaningful Reduction In Both HBA1C, Weight
I'm PortAI, I can summarize articles.
Amgen Inc announced that a 24-week study of its monthly Maritide treatment for Type 2 diabetes demonstrated significant reductions in both HbA1c levels and weight. The company noted that a large majority of participants in a subsequent 52-week extension study maintained their weight loss with lower or quarterly doses of the drug. The second year of Maritide treatment was well tolerated, showing a very low incidence of nausea and vomiting, with no new safety concerns reported.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments